scholarly journals Oral clopidogrel for chronic central serous chorioretinopathy: A short-term preliminary study

2013 ◽  
Vol 3 (1) ◽  
pp. 14-19
Author(s):  
Shih-Yun Lee ◽  
Chia-Chen Tsai ◽  
Shih-Jen Chen
Keyword(s):  
Central Serous Chorioretinopathy ◽  
Short Term ◽  
Chronic Central Serous Chorioretinopathy ◽  
Preliminary Study

scholarly journals Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Hamid-Reza Moein ◽  
Lauren W. Bierman ◽  
Eduardo A. Novais ◽  
Carlos Moreira-Neto ◽  
Caroline R. Baumal ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Prospective Study ◽  
Central Serous Chorioretinopathy ◽  
Subretinal Fluid ◽  
Enhanced Depth Imaging ◽  
Short Term ◽  
Chronic Central Serous Chorioretinopathy ◽  
Therapeutic Trials ◽  
Imaging Optical Coherence Tomography ◽  
A Prospective Study

Abstract Background Increased mineralocorticoid activity is one of the plausible causes of chronic central serous chorioretinopathy (CSCR) and mineralocorticoid inhibitors such as eplerenone have been investigated as its potential therapy. This study investigates the short-term safety and efficacy of oral eplerenone in patients with chronic CSCR. Patients and methods Prospective study of 13 eyes of 13 patients with the diagnosis of chronic CSCR. All patients received eplerenone 50 mg/day for 4 weeks. Enhanced depth imaging optical coherence tomography (OCT) was obtained. Best corrected visual acuity (BCVA), and OCT parameters including sub retinal fluid (SRF), choroidal thickness (CT) and central macular thickness (CMT), were measured manually. Results The mean SRF height decreased slightly at 1-month follow-up as compared to baseline, but the change was not statistically significant (94.18 ± 17.53 vs. 113.15 ± 18.69; p = 0.08). Subfoveal CT and CMT was significantly reduced as compared to baseline (6.6% [p = 0.002] and 7.05% [p = 0.04], respectively). The BCVA did not change significantly (20/28 vs. 20/30 [p = 0.16]). Conclusion This study suggests that oral eplerenone may be used as a safe and potentially effective treatment in chronic CSCR, however there are minimal short-term effects on subretinal fluid or visual acuity therefore therapeutic trials longer than one month are necessary to test its benefits. Trial registration Clinicaltrials.gov identification number: NCT01822561. Registered 3/25/13, https://clinicaltrials.gov/ct2/show/study/NCT01822561

scholarly journals The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Jianbo Mao ◽  
Caiyun Zhang ◽  
Chenyi Liu ◽  
Lijun Shen ◽  
Jimeng Lao ◽  
...  
Keyword(s):  
Repeated Measures ◽  
Central Serous Chorioretinopathy ◽  
Subretinal Fluid ◽  
Short Term ◽  
Chronic Central Serous Chorioretinopathy ◽  
Full Resolution ◽  
Repeated Measures Analysis ◽  
Retrospective Clinical Study ◽  
The Mean

Purpose. To evaluate the efficacy and safety of conbercept for patients with chronic central serous chorioretinopathy (CSC). Methods. A retrospective clinical study. Thirty-one patients (35 eyes) with chronic CSC were given intravitreal injections of conbercept and followed up for at least 6 months. Observed indicators included best-corrected visual acuity (BCVA), central macular thickness (CMT), and resolution of subretinal fluid (SRF). Serial changes in BCVA and CMT were analyzed by using repeated measures analysis of variance. Results. During the 6-month follow-up, the mean number of injections required and performed was 1.77 ± 0.60. The logMAR BCVA was 0.48 ± 0.26 at the baseline, 0.34 ± 0.26, 0.30 ± 0.26, 0.27 ± 0.26, 0.24 ± 0.26, and 0.23 ± 0.26 at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively (F = 27.173, P<0.05). CMT was 313.74 ± 144.51 μm at the baseline and decreased to 263.49 ± 120.44 μm, 225.91 ± 91.98 μm, 195.77 ± 66.69 μm, 189.74 ± 65.41 μm, and 199.49 ± 81.50 μm at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively (F = 18.093, P<0.05). Full resolution of SRF was achieved in 8 (22.9%) eyes at 1 month, 16 (45.7%) eyes at 2 months, 22 (62.9%) eyes at 3 months, and 27 (77.1%) eyes at 6 months after the initial treatment of anti-VEGF injection. No severe adverse event was noted relevant to the therapy. Conclusions. Intravitreal injection of conbercept may effectively reduce the CMT and improve the BCVA in chronic CSC in a short term of 6 months.

scholarly journals Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0245342
Author(s):  
Yong-Yeon Song ◽  
Hwa-Young Yu ◽  
Seung-Kook Baek ◽  
Young-Hoon Lee ◽  
Min-Woo Lee
Keyword(s):  
Optical Coherence Tomography ◽  
Choroidal Neovascularization ◽  
Central Serous Chorioretinopathy ◽  
Optical Coherence Tomography Angiography ◽  
Visual Outcome ◽  
Optical Coherence ◽  
Short Term ◽  
Chronic Central Serous Chorioretinopathy ◽  
Group 2 ◽  
Group 1

Purpose To analyze the short-term therapeutic efficacy of intravitreal injection of bevacizumab (IVB) for chronic central serous chorioretinopathy (CSC) according to the presence of choroidal neovascularization (CNV) using optical coherence tomography angiography (OCTA). Methods A retrospective chart review was perfomed on cases of CSC with CNV (Group 1: n = 31) and an age-matched cases of CSC without CNV (Group 2: n = 30). The response to IVB was evaluated by changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), choroidal thickness (CT), and pachyvessel diameter. Univariate and multivariate linear regression analyses were performed to identify factors associated with the visual outcome of chronic CSC with CNV after IVB. Results At baseline, the CT values differed significantly between Groups 1 and 2 (371.55 ± 67.09 vs. 417.33 ± 71.32 μm, p = 0.01). In Group 1, BCVA improved significantly (p < 0.001), and CMT (p < 0.001), CT (p = 0.001) and pachyvessel diameter (p = 0.045) decreased significantly, after IVB. In Group 2, only pachyvessel diameter (p = 0.001) was significantly smaller after IVB. Univariate analysis showed that the initial CT (B = 0.002, p = 0.026) and pachyvessel diameter (B = 0.002, p = 0.001) significantly affected visual outcome. In multivariate analysis, the initial pachyvessel diameter exhibited significant results (B = 0.002, p = 0.001). Conclusions IVB showed less effective short-term outcomes in chronic CSC patients without CNV than in patients with CNV. In chronic CSC with CNV, the short-term visual outcome after IVB was better in patients with a thinner choroid and smaller pachyvessels.

scholarly journals Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy

2020 ◽  
Vol 9 (9) ◽  
pp. 2734
Author(s):  
Camilla Alovisi ◽  
Felice Cardillo Piccolino ◽  
Marco Nassisi ◽  
Chiara M. Eandi
Keyword(s):  
Photodynamic Therapy ◽  
Central Serous Chorioretinopathy ◽  
Short Term ◽  
Chronic Central Serous Chorioretinopathy ◽  
Average Ratio ◽  
Half Dose ◽  
Baseline Status ◽  
Choroidal Structure ◽  
Total Structure ◽  
Binarization Method

The study aims to analyze the changes produced by half-dose photodynamic therapy (HD-PDT) in the choroid of eyes with chronic central serous chorioretinopathy (CSC) applying the binarization method to spectral domain optical coherence tomography (SDOCT) and OCT Angiography (OCTA) images. SDOCT and OCTA were performed before, one hour, one week, and one month after HD-PDT. Binarization with a modified Niblack method and analysis by ImageJ were applied. An average ratio between luminal part and total structure was calculated. Twenty-two eyes of 21 patients (20 male and 1 female; mean age 54.8 years) were enrolled. A statistically significant reduction of the central choroidal thickness was observed one week (from 407 µm to 362 µm, p = 0.034) and one month (from 407 µm to 341.5 µm, p = 0.0004) after HD-PDT. The baseline average ratio between luminal part and total structure was 33.4% in SDOCT, and 61.1% in OCTA. These values were 35.3% and 61% one hour, 33.9% and 60.4% one week, and 34.5% and 60.6% one month after HD-PDT, respectively. Overall, PDT seems to produce short-term changes on the luminal component of both choriocapillaris and choroid, which return to baseline status after one month from treatment. However, choroid stays significantly thinner after one month, with both luminal and interstitial components significantly reduced.

Sign in / Sign up

Export Citation Format

Share Document